A total of 9,712 diabetic patients, with histories of chronic kidney disease and heart failure, were identified for the study ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

A decision is expected in the fourth quarter of 2025.